# Feds Maintain Marijuana Testing Despite Cannabis Reclassification > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/federal-workplace-drug-testing-policies-marijuana/ > **Published:** 2026-03-17T07:22:38-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:06:15-04:00 > **Clinical Summary:** Explore federal workplace drug testing policies that continue screening for marijuana despite cannabis reclassification and its impact on employment. --- ✦ New CED Clinical Relevance #62 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyIndustrySafety Why This Matters Federal workplace [drug testing](https://cedclinic.com/how-long-does-weed-stay-in-your-system/) policies that continue screening for marijuana metabolites create a disconnect between legal reclassification efforts and employment consequences that clinicians should discuss with patients who use cannabis for medical purposes. Patients need to understand that federal reclassification does not protect them from positive drug tests in safety-sensitive positions or certain employment sectors, which may influence their treatment decisions and disclosure to employers. Clinicians should counsel patients that workplace drug testing remains a significant practical barrier to [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) regardless of its Schedule III status, particularly those in transportation, healthcare, or federally regulated industries. Clinical Summary Following the federal reclassification of cannabis to Schedule III, the Department of Health and Human Services has maintained existing workplace drug testing protocols that detect marijuana metabolites, despite expectations that the reclassification might prompt policy changes. The HHS announcement, published in the Federal Register, confirmed that federal drug testing panels will continue to screen for cannabis use without modifications, meaning employers subject to federal testing requirements will still identify marijuana use regardless of its new legal status. This decision creates a practical disconnect between cannabis’s reduced scheduling and workplace enforcement, potentially affecting patients who use cannabis therapeutically and may be subject to federal workplace drug testing requirements. The continued testing standards mean clinicians should counsel patients using cannabis medicinally about the persistent occupational risks, as federal employees, transportation workers, and those in federally regulated industries remain subject to detection and potential employment consequences. Patients and clinicians should be aware that therapeutic cannabis use does not protect workers from federal drug testing protocols, despite the drug’s regulatory reclassification. Dr. Caplan’s Take “What we’re seeing is a disconnect between federal rescheduling and workplace drug policy that creates real problems for my patients who use cannabis legally for chronic pain or anxiety—they can lose their jobs over a metabolite that has nothing to do with impairment or job performance, and that’s a policy failure we need to address head-on.” Clinical Perspective The federal government’s decision to maintain workplace marijuana testing protocols despite the Trump administration’s reclassification of cannabis reflects the ongoing tension between evolving drug policy and occupational safety frameworks that healthcare providers should understand when evaluating patients in safety-sensitive roles. While cannabis reclassification may shift medical and legal perspectives on the drug’s therapeutic potential, employers—particularly those in transportation, construction, and healthcare—continue to operate under federal testing mandates that clinicians cannot ignore when counseling working patients about cannabis use. Providers should recognize that a positive workplace drug screen remains a significant occupational consequence for patients regardless of state-level legalization or changing federal scheduling, and the persistence of these testing requirements means that even patients using cannabis legally or medicinally may face employment jeopardy. The distinction between cannabis’ legal reclassification and workplace testing policy also highlights the importance of clear documentation in clinical notes, as patients need to understand that federal employment protections and 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Feds+keep+marijuana+tests+for+workers+despite+Trump+reclassification+order+-+Yahoo+%40drcaplan&url=https%3A%2F%2Fwww.yahoo.com%2Fnews%2Farticles%2Ffeds-keep-marijuana-tests-workers-160800133.html)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.yahoo.com%2Fnews%2Farticles%2Ffeds-keep-marijuana-tests-workers-160800133.html)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Feds+keep+marijuana+tests+for+workers+despite+Trump+reclassification+order+-+Yahoo+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.yahoo.com%2Fnews%2Farticles%2Ffeds-keep-marijuana-tests-workers-160800133.html)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 230 Items — March 15, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-clinical-relevance-2026/) - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) 📰 Source: [https://www.yahoo.com/news/articles/feds-keep-marijuana-tests-workers-160800133.html](https://www.yahoo.com/news/articles/feds-keep-marijuana-tests-workers-160800133.html) Further Reading Cannabis Policy Wire[AM Policy Update: March 17, 2026](https://cedclinic.com/dea-synthetic-opioids-schedule-i-march-17-2026/) Evidence Watch[AM Study Update: March 17, 2026](https://cedclinic.com/full-spectrum-cannabis-extract-chronic-pain-update/) Research Digest[AM News Update: March 17, 2026](https://cedclinic.com/cannabis-clinical-trials-mental-health-march-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump administration eases rules on some marijuana categories – WUSF](https://cedclinic.com/trump-administration-marijuana-rescheduling-update/) Learn about recent federal policy changes easing restrictions on certain marijuana categories and their implications. [Read More](https://cedclinic.com/trump-administration-marijuana-rescheduling-update/) [Some practical tips regarding drug testing in Oklahoma – McAfee & Taft](https://cedclinic.com/employment-drug-testing-medical-cannabis-oklahoma-tips/) Practical guidance on navigating workplace drug testing policies in Oklahoma, relevant for cannabis users and employers. [Explore Tips](https://cedclinic.com/employment-drug-testing-medical-cannabis-oklahoma-tips/) [Legal Experts Caution Cannabis Industry on DEA Registration Following Medical … – Hemp Gazette](https://cedclinic.com/topic-legalization-info/) Insights from legal experts on DEA registration challenges for the [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) amid evolving regulations. [Learn More](https://cedclinic.com/topic-legalization-info/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).